18.04.2014 • NewsCarlyleCarlyle GroupDede Willams

Carlyle See Buyout Firms Focus on Emerging Markets

The global private equity industry will see more listed players in coming years, while focusing more on emerging markets, less on leverage and more on good management of their investments, a senior executive of the Carlyle Group said at an event in Rio de Janeiro, Brazil.

Buyout firms will have to focus on "value creation" or an active management to enhance returns on their investments, said Carlyle co-CEO David Rubenstein, He added that sovereign wealth funds will become the main source of money for the industry in coming years, an era he dubbed Private Equity 4.0.

One of the U.S. largest private-equity firms, Carlyle in January of this year acquired the diagnostics arm of U.S. pharmaceutical manufacturer Johnson & Johnson. In 2013 it bought the Performance Coatings business of U.S. chemical giant DuPont and in 2012 took a 13.5% stake in China's Meinian Onehealth Healthcare Group.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.